Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
- 18 April 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 133 (16), 1715-1719
- https://doi.org/10.1182/blood-2018-12-852376
Abstract
Blinatumomab, a bi-specific T cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.Keywords
This publication has 39 references indexed in Scilit:
- Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabJournal of Hematology & Oncology, 2015
- Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemiaBlood, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2014
- Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemiaBlood Cancer Journal, 2014
- Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemiaBlood, 2014
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood, 2012
- Toward victory in adult ALL: blinatumomab joins inBlood, 2012
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free SurvivalJournal of Clinical Oncology, 2011
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood, 2009